Hartrampf, P.E.; Weinzierl, F.-X.; Serfling, S.E.; Pomper, M.G.; Rowe, S.P.; Higuchi, T.; Seitz, A.K.; Kübler, H.; Buck, A.K.; Werner, R.A.
Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [177Lu]Lu-PSMA I&T. Cancers 2022, 14, 647.
https://doi.org/10.3390/cancers14030647
AMA Style
Hartrampf PE, Weinzierl F-X, Serfling SE, Pomper MG, Rowe SP, Higuchi T, Seitz AK, Kübler H, Buck AK, Werner RA.
Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [177Lu]Lu-PSMA I&T. Cancers. 2022; 14(3):647.
https://doi.org/10.3390/cancers14030647
Chicago/Turabian Style
Hartrampf, Philipp E., Franz-Xaver Weinzierl, Sebastian E. Serfling, Martin G. Pomper, Steven P. Rowe, Takahiro Higuchi, Anna Katharina Seitz, Hubert Kübler, Andreas K. Buck, and Rudolf A. Werner.
2022. "Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [177Lu]Lu-PSMA I&T" Cancers 14, no. 3: 647.
https://doi.org/10.3390/cancers14030647
APA Style
Hartrampf, P. E., Weinzierl, F.-X., Serfling, S. E., Pomper, M. G., Rowe, S. P., Higuchi, T., Seitz, A. K., Kübler, H., Buck, A. K., & Werner, R. A.
(2022). Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [177Lu]Lu-PSMA I&T. Cancers, 14(3), 647.
https://doi.org/10.3390/cancers14030647